Intron I of the rat osteocalcin gene contains silencer elements that suppress osteocalcin-reporter fusion gene transcription. The consensus sequence for the transcription factor ␦EF1 is homologous to two pyrimidine-rich repeats in intron 1 that contribute to silencing of osteocalcin-reporter fusion genes. To assess if overexpression of ␦EF1 augments transcriptional repression by these sequences, the intron 1 sequences (wtS) were placed upstream to the native rat osteocalcin promoter fused to a luciferase reporter gene (-306-OCluc). Coexpression of the wtS-(-306-OCluc) fusion gene with ␦EF1 decreased luciferase activity 30% relative to cotransfection with empty vector. Repression was abolished by point mutations in the putative ␦EF1 motifs, mS-(-306-OCluc).
O STEOCALCIN IS A GENE that is expressed by mature osteoblasts and odontoblasts. It is the second most abundant bone matrix protein after collagen. Although osteocalcin is a marker of mature osteoblasts and regulation of its expression provides a model for examining the tissuespecific expression of bone cell genes, how it contributes to the regulation of skeletal homeostasis remains unclear (1) . The development of the osteocalcin knockout mouse demonstrated that osteocalcin plays a negative role in bone formation by acting to limit bone formation without effects on resorption or mineralization (2) . This suggests that factors that repress transcription of the osteocalcin gene may lead to increased bone formation.
Several factors have been noted to regulate osteocalcin gene transcription, including 1,25-dihydroxyvitamin D 3 (3) , and the mammalian homolog of the Drosophila runt protein, CBFA1 (4) . Homeodomain proteins such as Msx-2 and Dlx-5 have also been shown to play a role in osteocalcin gene regulation, by decreasing osteocalcin reporter gene expression (5-7). The transcription factor YY1 has also been found to repress 1,25-dihydroxyvitamin D 3 induced transcription of the rat osteocalcin gene by interfering with the binding of the vitamin D receptor to its response element and the transcription factor TFIIB (8) . Glucocorticoids (9, 10) and TNF␣ (11) have also been shown to repress osteocalcin gene transcription.
Previous studies have identified unique silencer elements that contribute to the regulation of osteocalcin gene transcription (12, 13) . In particular, sequences in the first intron of the rat osteocalcin gene have been shown to suppress the activity of osteocalcin-chloramphenicol acetyl transferase fusion genes in the osteoblastic cell lines ROS 17/2.8 and UMR 106. Intron 1 of the rat osteocalcin gene contains two copies of a pyrimidine-rich CCTCCT motif, located at ϩ106 to ϩ111 and ϩ135 to ϩ140. Mutation of one or both of these motifs leads to impaired suppression of osteocalcin fusion genes in ROS 17/2.8 cells, indicating that these motifs interact with a transcription factor that contributes to the regulation of osteocalcin gene expression (14) .
A search of the transcription factor database Transfac identified several putative transcription factor consensus sequences in intron 1 of the osteocalcin gene. The consensus sequence for one of these factors, ␦EF1, was highly homologous to the two pyrimidine-rich motifs in intron 1. Because of this high degree of homology and the known repressive effects of ␦EF1 on type I and type II collagen gene expression (15, 16) , we examined the effects of ␦EF1 on osteocalcin gene expression.
Materials and Methods

Cell culture and transfections
ROS 17/2.8 cells were maintained in Ham's F-12 medium with lglutamine supplemented with 10% fetal bovine serum (Life Technologies, Inc., Gaithersburg, MD), penicillin, and streptomycin. Transfections were carried out by calcium phosphate precipitation in six-well plates as previously described (3) . COS 7 cells were grown in DMEM supplemented with 10% fetal bovine serum, penicillin, and streptomycin. Transfections were performed by diethylaminoethyl dextran. Osteocalcin-luciferase fusion genes, Ϫ306-OCluc, which contains the minimal promoter from -306 to ϩ29 subcloned into the SacI-XhoI sites of pGL3basic (Promega Corp., Madison, WI); wtS-(-306-OCluc), which contains the sequence of intron 1 from ϩ101 to ϩ142 placed upstream of the minimal promoter at the SacI site; and mS-(-306-OCluc), which contains mutations in the CCTCCT motifs in the ϩ101 to ϩ142 sequence (14) were cotransfected with Renilla luciferase under the control of the SV40 promoter (pRL-SV40) into ROS 17/2.8 cells and with pRL-thymidine kinase into COS 7 cells along with either pCMV (empty vector) or pCMVX-␦EF1 
Gel retardation assays
Oligonucleotides were synthesized corresponding to the sequences of interest, with GATC overhangs (Integrated DNA Technologies, Coralville, IA). Double-stranded oligonucleotides were labeled with ␣ 32 Pdeoxy-ATP by filling in recessed ends with the large fragment of DNA polymerase I. [Sense strand of oligonucleotide sequences used:
wild-type osteocalcin suppressor (wtOCS)ϭGATCTGCCCTCCTG-GTTCATTGCCCTCCTGTTCAT, mutant osteocalcin suppressor (mOCS)ϭGATCTGCATGCATGG-TTCATTGCATGCATGGTTCAT, wt␦EF1ϭGATCGTAATCTGGGCCACCTGCCTGGGAGGA, m␦EF1ϭGATCGTAATCTGGGCAAAATGCCTGGGAGGA.] Nuclear extracts were prepared as previously described (17) . Nuclear extracts from ROS 17/2.8 cells (4 g) were incubated for 20 min at room temperature in 10 l of ␦EF1 binding buffer (18) containing 2 g of poly(dA-dT)-poly(dA-dT) (Amersham Pharmacia Biotech, Piscataway, NJ). Then, 10-or 100-fold molar excess of nonlabeled competitor was added per reaction and incubated for an additional 20 min at room temperature. Alternatively, 1 l of polyclonal anti-␦EF1 antibody (a gift from Dr. Yujiro Higashi, Osaka University, Osaka, Japan) or antirabbit IgG (negative control) was added to reactions without competitor and incubated for 20 min. One nanogram of labeled probe was then added per reaction, incubated for an additional 20 min and the complexes were resolved through 4% polyacrylamide gels containing 22 mm Tris-borate (pH 8.0) and 0.5 mm EDTA at 4 C. The gels were dried and exposed to film overnight.
Northern analyses
Northern analysis was performed using RNA isolated from pooled clones of stably transfected ROS 17/2.8 cells between passages 2 and 6. Total RNA was prepared using Tri reagent (Sigma, St. Louis, MO) following the manufacturer's specifications. RNA was fractionated on 1% agarose gels and blotted overnight onto Biotrans nylon membranes (ICN Biochemicals, Aurora, OH) using standard techniques (19) . Hybridization was performed using random primed labeled cDNA probes and UltraHyb hybridization buffer (Ambion, Inc., Austin, TX) or QuikHyb (Stratagene, Cedar Creek, TX). A cDNA probe for GAPDH was used to correct for differences in the amount of RNA loaded per lane.
Densitometric analysis
Densitometry was performed using the spot densitometry program on the ␣ Imager 2200 Documentation and Analysis System (Alpha Innotech Corp., San Leandro, CA).
Results
ROS 17/2.8 cells have properties of mature osteoblasts and express several osteoblast markers, including osteocalcin and type I collagen (20) . Therefore, this cell line was used to examine the effects of the transcriptional repressor ␦EF1 on osteocalcin gene expression. To identify a potential role for ␦EF1 in regulating osteocalcin gene expression, the fusion gene containing the sequence of intron 1 from ϩ101 to ϩ142, including both putative ␦EF1 binding sites, was placed upstream of the native promoter (Ϫ306 to ϩ29) fused to a luciferase reporter [wtS-(-306-OCluc)]. When placed upstream of -306-OCluc, and transfected into ROS 17/2.8 cells, these sequences repress osteocalcin-luciferase activity by 44.4 ϩ 1.5% in the forward orientation and 31.4 ϩ 6% in the reverse orientation (14) . Mutations in the putative ␦EF1 consensus sequences, mS-(-306-OCluc), abolished this repression (14) .
Cotransfection of the ␦EF1 expression vector with the osteocalcin promoter-luciferase gene (-306-OCluc) did not affect luciferase activity relative to empty vector control (EV) in ROS 17/2.8 cells (Fig. 1) . However, when ␦EF1 was coexpressed with the wtS-(-306-OCluc) construct, there was a 31 Ϯ 2.5% decrease in luciferase activity relative to wtS-(-306-OCluc) cotransfected with EV. In contrast, there was no significant effect on luciferase activity observed when ␦EF1 was coexpressed with the mS-(-306-OCluc) fusion gene. These data indicate that the pyrimidine-rich motifs are important for ␦EF1-mediated repression of osteocalcin fusion gene expression. A 15% reduction in luciferase activity was noted when a luciferase fusion gene containing FIG. 1. Repression of osteocalcin expression by ␦EF1 in ROS 17/2.8 cells. Plasmids used are indicated on the x-axis. Firefly luciferase activity, corrected for cotransfected Renilla luciferase activity (y-axis) is expressed relative to empty vector, which is normalized to a value of one in each case. All values were obtained from at least three separate transfections performed using at least two different plasmid preparations. EV, Empty vector (pCMV); ␦EF1, pCMVX␦EF. *, P Ͻ 0.0005. the sequence from -1750 to ϩ147 was coexpressed in transient transfection assays with ␦EF1 in ROS 17/2.8 cells. However, this fusion gene contains numerous other response elements, including a TTTCTTT motif that has been shown to dramatically suppress osteocalcin reporter gene activity (21) . We, therefore, focused our analysis on the isolated CCTCCT motifs to specifically evaluate the ability of ␦EF1 to mediate transcriptional repression by these sequences.
To address whether the effects of ␦EF1 on transcriptional repression on osteocalcin luciferase fusion genes require interactions with osteoblast-specific transcription factors, COS 7 cells were also used for cotransfection studies. A 26 Ϯ 4% decrease in luciferase activity was detected when wtS-(-306-OCluc) was coexpressed with ␦EF1, relative to control cotransfection (EV) (Fig. 2) . There was no significant effect observed on luciferase activity when mS-(-306-OCluc) was cotransfected with ␦EF1, nor was there an effect when the promoter construct lacking the sequences from the first intron (-306-OCluc) was coexpressed with ␦EF1. These results indicate that ␦EF1 can mediate its repressive effects through the pyrimidine-rich motifs in the absence of osteoblastspecific factors.
To determine whether ␦EF1 binds directly to these pyrimidine-rich motifs, gel retardation assays were performed. Because ␦EF1 has been shown to bind to the immunoglobulin enhancer element with high affinity, this sequence (wt␦EF) was used as a control oligonucleotide for ␦EF1 binding in the gel shift assays. An oligonucleotide containing mutations in the ␦EF1 consensus sequence that has previously been shown to be unable to bind to ␦EF1 (m␦EF1) was used as a negative control (18) . When the sequences from ϩ101 to ϩ142 were used as a radiolabeled probe (wtOCS), several DNA-protein complexes were identified in nuclear extracts from ROS 17/ 2.8 cells (Fig. 3, A and B) . Addition of a polyclonal antibody raised against ␦EF1 competed for the formation of a specific DNA-protein complex (arrow, Fig. 3A ) (lane 2). A nonspecific IgG from the same species did not affect the formation of this complex (lane 3). This same complex was competed for by excess unlabeled wtOCS and wt␦EF oligonucleotides (Fig.   3B, lanes 2 and 3, and 6 and 7) . Oligonucleotides containing mutations in the putative osteocalcin ␦EF1 motifs (mOCS) (lanes 4 and 5) and in the ␦EF binding site (m␦EF) (lanes 8 and 9) were unable to compete for the formation of this complex.
When the wt␦EF oligonucleotide was used as a radiolabeled probe, numerous complexes comigrating with those observed using the wtOCS probe were formed (Fig. 3A, lane  4) . The polyclonal antibody directed against ␦EF1 similarly interfered with the formation of the specific DNA-protein complex indicated by the arrow (lane 5). Complex formation was not affected by the addition of nonspecific IgG (lane 6). Unlabeled 10-and 100-fold molar excess wtOCS (Fig. 3C , lanes 11 and 12) was able to compete for the formation of this complex, whereas the mOCS oligonucleotide was not (lanes 13 and 14). As expected, the same wild-type ␦EF1 consensus site oligonucleotide competed for the formation of this complex (lanes 15 and 16), whereas the mutant oligonucleotide did not (lanes 17 and 18). Gel shift assays performed using nuclear extracts isolated from ROS 17/2.8 cells stably overexpressing ␦EF1 showed identical antibody recognition and competition with the wtOCs and ␦EF probes (data not shown). Mutant probes failed to generate comigrating bands or complexes competed for by the wild-type oligonucleotides.
To determine whether overexpression of ␦EF1 suppresses the expression of the endogenous osteocalcin gene, ROS 17/2.8 cells were stably transfected with either empty vector or the ␦EF1 expression vector. After selection with geneticin for 14 d, 2 pools of 50 clones from each of the empty vector and ␦EF1 transfected cells were used for further studies. RNA was isolated from cells between passages 2 and 6. Northern analyses demonstrated a 5.65 Ϯ 0.21-fold increase in ␦EF1 mRNA levels in the pooled clones transfected with the ␦EF1 expression vector relative to the low levels of endogenous ␦EF1 in the pooled empty vector transfected clones (Fig. 4, A and B) . The ␦EF1 overexpressing clones also demonstrated an 84 Ϯ 5% decrease in endogenous osteocalcin mRNA levels compared with those clones stably transfected with empty vector. These   FIG. 2 . Repression of osteocalcin expression by ␦EF1 in COS 7 cells. Plasmids used are indicated on the x-axis. Firefly luciferase activity, corrected for cotransfected Renilla luciferase activity (y-axis) is expressed relative to empty vector, which is normalized to a value of one. All values were obtained from at least three separate transfections performed using at least two different plasmid preparations. EV, Empty vector (pCMV); ␦EF1, pCMVX␦EF. *, P Ͻ 0.0005. data confirm that the repression of osteocalcin-luciferase fusion gene expression by ␦EF1 in the transient gene expression assays reflects the actions of ␦EF1 on transcription of the endogenous osteocalcin gene.
Computerized homology searches (BestFit; University of Wisconsin) also revealed putative ␦EF1 motifs in other osteoblast genes, notably type I collagen, osteopontin, alkaline phosphatase and the PTH/PTHrP receptor. To determine if ␦EF1 also regulated these genes, northern analyses were performed using RNA isolated from the pooled clones stably transfected with either ␦EF1 or empty vector. RNA from cells overexpressing ␦EF1 demonstrated a 21 Ϯ 2% decrease in type I collagen RNA expression relative to cells transfected with empty vector (Fig. 4B) . This result was consistent with those obtained by Terraz et al. (15) , who observed a 35% decrease in type I collagen mRNA in ROS 17/2.8 cells overexpressing ␦EF1. We also observed a 45 Ϯ 3%-fold decrease in alkaline phosphatase mRNA levels in cells overexpressing ␦EF1 relative to cells transfected with the empty vector (Fig. 4B) . No changes in the levels of mRNA encoding either the PTH/PTHrP receptor (Fig. 4B ) or osteopontin were observed (data not shown).
Discussion
␦-Crystallin enhancer factor 1, ␦EF1, is a 124-kDa DNA binding protein that consists of a central homeodomain and two sets of seven Kruppel-type zinc fingers at the N and C termini (22) (23) (24) . A vertebrate homolog of the Drosophila protein zfh-1, ␦EF1 is a widely distributed repressor of transcription that was found to preferentially bind to the sequence (C/T)(A/T)C(C/G)T in the ␦-crystallin enhancer (22) . Although ␦EF1 was initially characterized in studies of the lens-specific regulation of the avian gene encoding ␦-crystallin, its broad tissue distribution suggests that ␦EF1 plays a more global role in the regulation of genes in several tissues (25) . ␦EF1 mRNA has been detected in all murine tissues examined (26) and is expressed as early as embryonic d 9.5 in the limb bud of the mouse (27) .
Engineering of the ␦EF1 knockout mouse demonstrated an important role for ␦EF1 in skeletal morphogenesis. Mice lacking ␦EF1 exhibited a variety of skeletal defects, including cleft palate, shortened mandible, shortening and broadening of long bones, fusion of joints, as well as fusion of the carpal and tarsal bones and hypoplasia of intervertebral discs (27) . In addition to its role in skeletal development, ␦EF1 was also 1-3; B) or a ␦EF1 consensus sequence (A, lanes 4 -6; C) were used as radiolabeled probes (wtOCS and wt␦EF1) with nuclear extracts from ROS 17/2.8 cells. Competition was performed using 10-and 100-fold molar excess of unlabeled double stranded olignucleotides. A, Lane 1, wtOCS probe control; lane 2, ␦EF1 antibody; lane 3, control IgG; lane 4, wt␦EF1 probe control; lane 5, ␦EF1 antibody; lane 6, control IgG. B, wtOCS probe. Lane 1, wtOCS probe control; lanes 2 and 3, 10-and 100-fold excess unlabeled wtOCS; lanes 4 and 5, 10-and 100-fold excess unlabeled mOCS; lanes 6 and 7, 10-and 100-fold excess unlabeled wt␦EF1; lanes 8 and 9, 10-and 100-fold excess unlabeled m␦EF1. C, wt␦EF1 probe. Lane 10, wt␦EF1 probe control; lanes 11 and 12, 10-and 100-fold excess unlabeled wtOCS; lanes 13 and 14, 10-and 100-fold excess unlabeled mOCS; lanes 15 and 16, 10-and 100-fold excess unlabeled wt␦EF1; lanes 17 and 18, 10-and 100-fold excess unlabeled m␦EF1.
found to be essential for normal T cell and thymus development, with mutant mice having 1% of the total lymphocyte number of wild-type mice (26) .
Studies examining the role of ␦EF1 on skeletal genes demonstrated that this transcription factor negatively regulates the Coll2a1 gene in chick sternal chondrocytes (16) . These cells express minimal levels of ␦EF1 mRNA and abundant type II collagen. Treatment of these cells with the growth factors basic fibroblast growth factor and TGF␤ results in an increase in ␦EF1 mRNA expression paralleled by a decrease in Coll2aI mRNA. These data suggested that ␦EF1 might suppress chondrocyte specific genes in the limb bud before the onset of chondrogenesis (16) .
Recent studies have demonstrated that ␦EF1 is able to repress type 1 collagen (␣1-1 col) gene expression in ROS 17/2.8 cells (15) . A 123-bp repressor element, collageninhibitory element-1, located 14 kb upstream of the transcriptional start site of the type I collagen gene, consists of three copies of a 41-bp repeat, each of which contain a ␦EF1 consensus sequence. Point mutations in these motifs abolished both binding of ␦EF1 to this element and repression by ␦EF1. Another ␦EF1/Zfh-1 family member, Smad interacting protein-1, has been shown to repress bone morphogenic protein-2-induced alkaline phosphatase activity in C2C12 cells (28) . Our studies demonstrate that ␦EF1, in addition to its effects on osteocalcin gene expression, is able to repress both alkaline phosphatase and ␣1-1col mRNA levels in ROS 17/ 2.8 cells.
Previous studies have identified unique silencer elements in the first exon and intron of the rat osteocalcin gene that contribute to gene regulation. A sequence from ϩ24 to ϩ151, containing part of the coding region of the first exon along with the 5Ј region of the first intron, was shown to significantly decrease transcription of osteocalcin fusion genes in both the native context and in an orientation-dependent manner when located 3Ј to the chloramphenicol acetyl transferase reporter gene (12, 13) . Mutation of another sequence, TTTCTTT, located at ϩ118 to ϩ124, between the two CCTCCT motifs examined in this study, markedly impaired silencing by sequences in the first intron, suggesting the factor that interacts with this motif may be a key regulator in osteocalcin gene expression (21) . These studies, and those reported herein, demonstrate the importance of intronic sequences in the regulation of osteocalcin gene expression.
The repressive effect of ␦EF1 on osteocalcin, alkaline phosphatase, and collagen gene expression points to an important role for this transcription factor in the regulation of bone formation. The dramatic suppression of the endogenous osteocalcin mRNA by ␦EF1 relative to the modest suppression of the wtS-(-306-OCluc) fusion gene, likely reflects functional interactions of this transcription factor with numerous other putative ␦EF1 motifs in the 5Ј regulatory region of the osteocalcin gene. Like the intronic ␦EF1 motifs, these motifs are present in the human and rat osteocalcin genes. In the mouse limb bud, ␦EF1 is expressed at high levels at embryonic d 9.5 and gradually decreases, being undetectable at the time of condensation of mesenchymal cells that give rise to the cartilaginous mold (27) . Following this stage, expression of osteoblast genes including alkaline phosphatase (embryonic d 13.5), type I collagen (embryonic d 14.0), and osteocalcin (embryonic d 18) is observed, suggesting that the decrease in ␦EF1 expression may lead to derepression of these genes. Our data, examining the effects of ␦EF1 on the levels of mRNAs encoding these genes, suggest that ␦EF1 acts to suppress or limit the osteoblast phenotype. This may occur at one of several stages. ␦EF1 may act to attenuate osteoblast differentiation, reflected by decreased expression of osteoblast genes, including type I collagen, alkaline phosphatase and osteocalcin. However, because ␦EF1 represses expression of these genes in ROS 17/2.8 cells, a model of mature osteoblasts, the principal skeletal effects of this transcription factor, after skeletal morphogenesis, may be in the postproliferative osteoblast. ␦EF1 may play a role in suppressing matrix synthesis by lining osteoblasts and/or osteocytes. Alternatively, transcriptional repression of the genes encoding the two most abundant bone matrix proteins, type I collagen and osteocalcin, may reflect a key role for ␦EF1 in limiting matrix formation during bone remodeling. Due to the perinatal lethality of the ␦EF1 knockout mice, the role of this transcription factor in skeletal maturation and remodeling remain unclear. However, the suppression of osteocalcin, type I collagen, and alkaline phosphatase gene expression by ␦EF1 and other family members suggest that this family of transcription factors may play a key role in skeletal homeostasis.
